We are live on ! Find out more
INZY

Inozyme Pharma
INZY

Delisted

INZY was delisted on the 30th of June, 2025.

Back to rankings

54 hedge funds and large institutions have $379M invested in Inozyme Pharma in 2020 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 20 increasing their positions, 7 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

186% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 7

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

10% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 10

8.8% more ownership

Funds ownership: 69.77% → 78.57% (+8.8%)

2% more funds holding

Funds holding: 53 → 54 (+1)

11% less capital invested

Capital invested by funds: $428M → $379M (-$48.7M)

Holders
54
Holders Change
+1
Holders Change %
+1.89%
% of All Funds
0.96%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.07%
New
11
Increased
20
Reduced
7
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SCM
Suvretta Capital Management
New York
+$5.11M
2
BCM
Burrage Capital Management
Massachusetts
+$4.07M
3
Wellington Management Group
Wellington Management Group
Massachusetts
+$3.19M
4
BlackRock
BlackRock
New York
+$3.09M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$2.3M

Top Sellers

Rank Fund Capital Flow
1
SFM
Sphera Funds Management
Israel
-$5.16M
2
APM
Avidity Partners Management
Texas
-$1.24M
3
RSCM
Rock Springs Capital Management
Maryland
-$1.18M
4
MF
Magnetar Financial
Illinois
-$633K
5
CA
CHI Advisors
New York
-$327K
Name Holding Trade Value Shares
Change 		Change in
Stake
Goldman Sachs
26
Goldman Sachs
New York
$430K +$171K +7,159 +52%
Morgan Stanley
27
Morgan Stanley
New York
$405K +$438K +18,402 +1,471%
OMC
28
Overbrook Management Corp
New York
$345K – – –
California Public Employees Retirement System
29
California Public Employees Retirement System
California
$324K -$7.15K -300 -2%
California State Teachers Retirement System (CalSTRS)
30
California State Teachers Retirement System (CalSTRS)
California
$254K – – –
D.E. Shaw & Co
31
D.E. Shaw & Co
New York
$248K +$286K +12,016 New
State of Wisconsin Investment Board
32
State of Wisconsin Investment Board
Wisconsin
$235K +$272K +11,400 New
LCM
33
Laurion Capital Management
New York
$212K – – –
APM
34
Avidity Partners Management
Texas
$200K -$1.24M -52,172 -84%
Wells Fargo
35
Wells Fargo
California
$200K +$85.4K +3,583 +59%
PNC Financial Services Group
36
PNC Financial Services Group
Pennsylvania
$188K +$218K +9,136 New
DekaBank Deutsche Girozentrale
37
DekaBank Deutsche Girozentrale
Germany
$170K +$167K +7,000 New
Ensign Peak Advisors
38
Ensign Peak Advisors
Utah
$165K – – –
New York State Common Retirement Fund
39
New York State Common Retirement Fund
New York
$153K +$176K +7,400 New
Deutsche Bank
40
Deutsche Bank
Germany
$127K +$40.9K +1,716 +39%
JP Morgan Chase
41
JP Morgan Chase
New York
$79K +$19.2K +807 +27%
CLOS
42
Compagnie Lombard Odier SCmA
Switzerland
$52K – – –
Citigroup
43
Citigroup
New York
$46K +$44K +1,846 +473%
SO
44
STRS Ohio
Ohio
$41K – – –
Bank of Montreal
45
Bank of Montreal
Ontario, Canada
$33K +$21.2K +890 +237%
TRCT
46
Tower Research Capital (TRC)
New York
$29K +$3.36K +141 +11%
Legal & General Group
47
Legal & General Group
United Kingdom
$18K – – –
AIP
48
Ameritas Investment Partners
Nebraska
$14K – – –
PCM
49
Penserra Capital Management
California
$11K +$12.7K +535 New
Royal Bank of Canada
50
Royal Bank of Canada
Ontario, Canada
$5K +$6K +252 +2,520%
1
2
3

INZY Hedge Fund Activity: Q4 2020 in Review

54 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Inozyme Pharma (INZY) for Q4 2020, worth a combined $379M — down 11% from $428M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new INZY positions and 10 closed out — a net gain of 1 holder — while 20 added to existing stakes and 7 trimmed.

The largest buyer was Suvretta Capital Management, opening a new position worth an estimated $5.11M. The largest seller was Sphera Funds Management, exiting entirely with an estimated $5.16M sold.

  • 54 institutional investors held Inozyme Pharma (INZY) as of Q4 2020, up from 53 in Q3 2020.
  • Funds reported $379M of Inozyme Pharma stock for Q4 2020, down 11% quarter-over-quarter.
  • 11 funds opened new Inozyme Pharma positions in Q4 2020 and 10 closed out, a net change of +1 holder.
  • The largest Inozyme Pharma buyer in Q4 2020 was Suvretta Capital Management, an estimated $5.11M added.
  • The largest Inozyme Pharma seller in Q4 2020 was Sphera Funds Management, an estimated $5.16M sold.

Based on aggregated 13F filings for Q4 2020.